Small Lymphocytic Lymphoma
📧 Sign up to get email alerts when something new happens for Small Lymphocytic Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-08-08Clinical Trial Update: Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Clinical trial updating on the use of entospletinib with obinutuzumab in relapsed CLL/SLL or NHL; Phase 1/2 study status completed with resu…
-
CLINICAL_TRIALS trial_result · 2023-07-27Clinical Trial Update: A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia [Phase 3]
Phase 3 study comparing zanubrutinib to ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma has com…
-
CLINICAL_TRIALS trial_result · 2023-07-24Clinical Trial Update: Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma [Phase 2]
Phase 2 trial of umbralisib plus ublituximab in treatment-naïve follicular lymphoma was terminated; results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-07-13Clinical Trial Update: Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects [Phase 1, Phase 2]
Phase I/II trial update for TL-895 with navtemadlin in treatment-naïve and relapsed/refractory B cell malignancies, including CLL/SLL and re…
-
CLINICAL_TRIALS trial_result · 2023-06-27Clinical Trial Update: Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL [Phase 2]
Phase 2 trial evaluating bendamustine/rituximab induction followed by maintenance rituximab and lenalidomide in previously untreated CLL/SLL…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-06-09Clinical Trial Update: High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant [Phase 2]
Phase 2 clinical trial evaluating high-dose cyclophosphamide, tacrolimus, and mycophenolate mofetil to prevent graft-versus-host disease in …
-
CLINICAL_TRIALS trial_result · 2023-06-05Clinical Trial Update: ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL [Phase 3]
A Phase 3 trial comparing ICP-022 to chlorambucil plus rituximab in untreated CLL/SLL is underway, with status currently unknown.
-
FDA approval · 2023-06-05FDA Approved: BENDAMUSTINE — Original Application (Meitheal Pharmaceuticals Inc.)
The FDA approved the original application for Bendamustine HCl from Meitheal Pharmaceuticals Inc., sanctioning a generic version of bendamus…
-
CLINICAL_TRIALS trial_result · 2023-04-19Clinical Trial Update: Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [Phase 2]
A Phase 2 trial evaluating the combination of ibrutinib, fludarabine, and pembrolizumab in high-risk or relapsed/refractory chronic lymphocy…
-
FDA approval · 2023-03-24FDA Approved: LENALIDOMIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for lenalidomide submitted by Sun Pharmaceutical Industries, Inc.
-
FDA approval · 2023-03-24FDA Approved: LENALIDOMIDE — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for Lenalidomide submitted by Aurobindo Pharma Limited to support the continued availability of …
-
CLINICAL_TRIALS trial_result · 2023-03-21Clinical Trial Update: Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas [Phase 2]
Phase 2 trial of pembrolizumab alone or with idelalisib or ibrutinib in relapsed/refractory chronic lymphocytic leukemia or various low-grad…
-
FDA approval · 2023-03-06FDA Approved: LENALIDOMIDE — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical Industries' generic lenalidomide (LENALIDOMIDE) under ANDA211846.
-
FDA approval · 2023-03-06FDA Approved: LENALIDOMIDE — Original Application (Mylan Pharmaceuticals Inc.)
FDA approved Lenalidomide from Mylan Pharmaceuticals as an original application (ANDA), marking the approval of a generic lenalidomide.
-
FDA approval · 2023-03-06FDA Approved: LENALIDOMIDE — Original Application (Aurobindo Pharma Limited)
FDA approved Lenalidomide as a generic product under an original application from Aurobindo Pharma Limited.
-
FDA approval · 2023-03-06FDA Approved: LENALIDOMIDE — Original Application (Teva Pharmaceuticals, Inc.)
FDA approved a generic lenalidomide product for Teva under ANDA201452, expanding access to lenalidomide formulations.
-
FDA approval · 2023-03-06FDA Approved: LENALIDOMIDE — Original Application (Alvogen, Inc.)
FDA approved Alvogen, Inc.'s original Abbreviated New Drug Application for a generic lenalidomide product (ANDA 210480).
-
FDA approval · 2023-03-06FDA Approved: LENALIDOMIDE — Original Application (EXELAN PHARMACEUTICALS INC.)
FDA approves a generic lenalidomide product from Exelan Pharmaceuticals under an original application. The drug is indicated for several hem…
-
CLINICAL_TRIALS trial_result · 2023-02-21Clinical Trial Update: A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07 [Phase 3]
Phase 3 extension study in chronic lymphocytic leukemia/small lymphocytic lymphoma evaluating duvelisib with ofatumumab has completed enroll…
-
CLINICAL_TRIALS trial_result · 2023-02-09Clinical Trial Update: Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma [Phase 1]
Phase I trial evaluating a combination of Vincristine Sulfate Liposome Injection with Bendamustine and Rituximab in indolent B-cell lymphoma…
-
FDA approval · 2023-02-08FDA Approved: LENALIDOMIDE — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approves Sun Pharmaceutical Industries' Lenalidomide Original Application, granting a generic lenalidomide product for multiple myeloma …
-
CLINICAL_TRIALS trial_result · 2023-01-31Clinical Trial Update: Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL [Phase 1, Phase 2]
Dose-escalation early-stage trial assessing safety of PBCAR20A in relapsed/refractory Non-Hodgkin's Lymphoma and relapsed/refractory Chronic…
-
FDA approval · 2023-01-19FDA Approved: BRUKINSA — Supplemental Application (BeOne Medicines USA, Inc.)
FDA approved a supplemental application for BRUKINSA (zanubrutinib) submitted by BeOne Medicines USA, Inc.
-
FDA approval · 2022-12-07FDA Approved: VIVIMUSTA — Original Application (Azurity Pharmaceuticals, Inc.)
FDA approved VIVIMUSTA (bendamustine hydrochloride) from Azurity Pharmaceuticals under Original Application NDA212209.
-
FDA approval · 2022-12-07FDA Approved: BENDAMUSTINE HYDROCHLORIDE — Original Application (Apotex Corp)
FDA approved bendamustine hydrochloride via Apotex Corp's original application, indicating the approval of a Bendamustine HCl product.